Literature DB >> 14718801

Treatment and care of neurotoxicity from taxane anticancer agents.

Haruhiko Makino1.   

Abstract

Taxane anticancer agents play a central role in drug therapy for breast cancer today; however, they have a dose-limiting neurotoxicity that is difficult to prevent and treat. To protect against this neurotoxicity it is important to avoid large doses greater than 200 mg/m2, and to adopt 24-hour administration regimens. Care is also needed with regard to the cumulative dose. Glutamine and amitriptyline are two of the very few drugs that have been found to be clinically effective against drug-induced peripheral neuropathy. Drugs are discontinued if neuropathy appears. If administration is to be later restarted, it is recommended that combined use of glutamine or amitriptyline be considered and that patients be given guidance for daily life.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14718801     DOI: 10.1007/bf02968011

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  5 in total

Review 1.  [Depression in cancer patients].

Authors:  Barbara Sperner-Unterweger
Journal:  Wien Med Wochenschr       Date:  2015-07-04

2.  Proposed medications for taxane-induced myalgia and arthralgia (Review).

Authors:  Atsushi Imai; Kazutoshi Matsunami; Hiroshi Takagi; Satoshi Ichigo
Journal:  Oncol Lett       Date:  2012-03-23       Impact factor: 2.967

3.  Melatonin, a promising role in taxane-related neuropathy.

Authors:  Z Nahleh; J Pruemer; J Lafollette; S Sweany
Journal:  Clin Med Insights Oncol       Date:  2010-04-28

4.  Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study).

Authors:  Katsumasa Kuroi; Kojiro Shimozuma; Yasuo Ohashi; Kazufumi Hisamatsu; Norikazu Masuda; Ayano Takeuchi; Toshihiko Aranishi; Satoshi Morita; Shozo Ohsumi; Frederick H Hausheer
Journal:  Support Care Cancer       Date:  2008-12-17       Impact factor: 3.603

5.  Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience.

Authors:  Bhavana Bhatnagar; Steven Gilmore; Olga Goloubeva; Colleen Pelser; Michelle Medeiros; Saranya Chumsri; Katherine Tkaczuk; Martin Edelman; Ting Bao
Journal:  Springerplus       Date:  2014-07-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.